-
EP3440108
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3440108
| EP3440108 - TREATMENT OF DEPRESSION USING AGENTS THAT BLOCK BINDING OF IL-6 TO IL-6 RECEPTOR [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 06.11.2020 Database last updated on 29.06.2024 | |
| Former | Request for examination was made Status updated on 11.01.2019 | ||
| Former | The international publication has been made Status updated on 13.10.2017 | Most recent event Tooltip | 13.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Janssen Biotech, Inc. 800/850 Ridgeview Drive Horsham, PA 19044 / US | [2019/07] | Inventor(s) | 01 /
CHEN, Guang 3210 Merryfield Row San Diego, California 92121 / US | 02 /
SUN, Yu 1800 American Boulevard Pennington, New Jersey 08534 / US | 03 /
WANG, Dai 100 US Highway 202 South Raritan, New Jersey 08869 / US | 04 /
WITTENBERG, Gayle 1125 Trenton-Harbourton Road Titusville, New Jersey 08560 / US | [2019/07] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
| Former [2019/07] | Wise, Daniel Joseph Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 17779843.6 | 06.04.2017 | [2019/07] | WO2017US26395 | Priority number, date | US201662319558P | 07.04.2016 Original published format: US 201662319558 P | [2019/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2017177032 | Date: | 12.10.2017 | Language: | EN | [2017/41] | Type: | A2 Application without search report | No.: | EP3440108 | Date: | 13.02.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 12.10.2017 takes the place of the publication of the European patent application. | [2019/07] | Search report(s) | International search report - published on: | US | 16.11.2017 | (Supplementary) European search report - dispatched on: | EP | 09.12.2019 | Classification | IPC: | C07K16/24, C07K16/18, C07K16/28, A61K39/395, G01N33/68, A61P25/24 | [2020/02] | CPC: |
C07K16/248 (EP,US);
A61P25/00 (EP);
A61P25/24 (EP);
A61P29/00 (EP);
A61K2039/505 (EP,US);
A61K2039/54 (US);
A61K2039/545 (US);
C07K2317/21 (US);
C07K2317/24 (US);
|
| Former IPC [2019/07] | C07K16/24, C07K16/18, C07K16/28, A61K39/395, G01N33/68 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/07] | Extension states | BA | 07.11.2018 | ME | 07.11.2018 | Validation states | MA | 07.11.2018 | MD | 07.11.2018 | Title | German: | BEHANDLUNG VON DEPRESSION MITHILFE VON WIRKSTOFFEN, DIE DIE BINDUNG VON IL-6 AN DEN IL-6-REZEPTOR BLOCKIEREN | [2019/07] | English: | TREATMENT OF DEPRESSION USING AGENTS THAT BLOCK BINDING OF IL-6 TO IL-6 RECEPTOR | [2019/07] | French: | TRAITEMENT DE LA DÉPRESSION À L'AIDE D'AGENTS QUI BLOQUENT LA LIAISON DE L'IL-6 AU RÉCEPTEUR DE L'IL-6 | [2019/07] | Entry into regional phase | 07.11.2018 | National basic fee paid | 07.11.2018 | Search fee paid | 07.11.2018 | Designation fee(s) paid | 07.11.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 07.11.2018 | Examination requested [2019/07] | 16.07.2020 | Amendment by applicant (claims and/or description) | 10.11.2020 | Despatch of a communication from the examining division (Time limit: M06) | 21.06.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 01.09.2021 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 01.09.2021 | Request for further processing filed | 01.09.2021 | Full payment received (date of receipt of payment) Request granted | 10.09.2021 | Decision despatched | Fees paid | Renewal fee | 15.04.2019 | Renewal fee patent year 03 | 31.03.2020 | Renewal fee patent year 04 | 15.04.2021 | Renewal fee patent year 05 | 14.03.2022 | Renewal fee patent year 06 | 14.03.2023 | Renewal fee patent year 07 | 13.03.2024 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI] - GEORGIA E. HODES ET AL, "Integrating Interleukin-6 into depression diagnosis and treatment", NEUROBIOLOGY OF STRESS, (20160329), vol. 4, doi:10.1016/j.ynstr.2016.03.003, ISSN 2352-2895, pages 15 - 22, XP055643723 [X] 1-3,5-9 * the whole document * * see in particular abstract; page 17, right-col. to page 18, left-col.; page 19, right-col. to page 20, left-col; * [I] 4,10-15 DOI: http://dx.doi.org/10.1016/j.ynstr.2016.03.003 | [XI] - SUN YU ET AL, "The Effect of IL-6 Neutralizing Agents on Depressed Mood and Anhedonia in Immunology and Oncology Clinical Trials", NEUROPSYCHOPHARMACOLOGY, & 54TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-NEUROPSYCHOPHARMACOLOGY (ACNP); HOLLYWOOD, FL, USA; DECEMBER 06 -10, 2015, (201512), vol. 40, no. Suppl. 1, pages S181 - S182, XP009517324 [X] 1-9 * the whole document * [I] 10-15 | [XI] - B. HSU ET AL, "SAT0182?Improvement in Measures of Depressed Mood and Anhedonia, and Fatigue, In a Randomized, Placebo-Controlled, Phase 2 Study of Sirukumab, A Human Anti-Interleukin-6 Antibody, In Patients with Rheumatoid Arthritis", ANNALS OF THE RHEUMATIC DISEASES, GB, (20150609), vol. 74, no. Suppl 2, doi:10.1136/annrheumdis-2015-eular.4081, ISSN 0003-4967, pages 720.3 - 721, XP055643690 [X] 1-3,5-7,9-11,13 * the whole document * [I] 4,8,14,15 DOI: http://dx.doi.org/10.1136/annrheumdis-2015-eular.4081 | [XI] - D Wang ET AL, "Interleukin-6 antibody Sirukumab improves depressive symptoms in a randomized, placebo-controlled, phase 2 study in patients with rheumatoid arthritis", (20150925), URL: https://www.europeanneuropsychopharmacology.com/article/S0924-977X(15)30625-8/pdf, (20181023), XP055518271 [X] 1-3,5-7,9 * the whole document * [I] 4,8,10-15 | [XI] - Yu Sun ET AL, "P.2.b.033 Siltuximab improves depressive symptoms in a randomised, placebo-controlled, phase 2 study in patients with multicentric Castlemen's disease", (20150901), URL: https://www.sciencedirect.com/science/article/pii/S0924977X15305320?via%3Dihub, (20191118), XP055643736 [X] 1,2,4-6,8,9 * the whole document * [I] 3,7,10-15 DOI: http://dx.doi.org/10.1016/S0924-977X(15)30532-0 | [XI] - FRITS VAN RHEE ET AL, "Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab", THE PATIENT - PATIENT-CENTERED OUTCOMES RESEARCH, (20150304), vol. 8, no. 2, doi:10.1007/s40271-015-0120-5, ISSN 1178-1653, pages 207 - 216, XP055643715 [X] 1,2,4-6,8,9,12,13 * the whole document * * see in particular abstract; page 208, left-hand col; pages 209, 213-215, Fig. 1, 3-5 * [I] 3,7,10,11,14,15 DOI: http://dx.doi.org/10.1007/s40271-015-0120-5 | [A] - JOSEF S SMOLEN ET AL, "Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy", ANNALS OF THE RHEUMATIC DISEASES, GB, (20140403), vol. 73, no. 9, doi:10.1136/annrheumdis-2013-205137, ISSN 0003-4967, pages 1616 - 1625, XP055644870 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1136/annrheumdis-2013-205137 | [T] - SUN YU ET AL, "The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease", BRAIN, BEHAVIOR AND IMMUNITY, (201711), vol. 66, doi:10.1016/J.BBI.2017.06.014, ISSN 0889-1591, pages 156 - 164, XP085228074 [T] * the whole document * DOI: http://dx.doi.org/10.1016/j.bbi.2017.06.014 | [T] - Douglas Strassler, "Sirukumab Relieves Depression in Patients With Rheumatoid Arthritis - Rheumatology Advisor", (20170716), URL: https://www.rheumatologyadvisor.com/home/topics/rheumatoid-arthritis/sirukumab-relieves-depression-in-patients-with-rheumatoid-arthritis/, (20191118), XP055643685 [T] * the whole document * | [T] - Sharon Worcester, "FDA committee rejects sirukumab approval on safety concerns | MDedge Rheumatology", (20170802), URL: https://www.mdedge.com/rheumatology/article/143848/rheumatoid-arthritis/fda-committee-rejects-sirukumab-approval-safety, (20191118), XP055643705 [T] * the whole document * | International search | [XY]US2014302058 (BOWEN MICHAEL [US], et al) [X] 1-3, 5/1-3, 10/5/1-3, 11/5/1-3, 13/1-3, 14/1-3 * ; table 3; abstract; paragraphs [0004], [0007], [0009], [0011], [0015], [0017], [0018], [0036], [0049]-[0050], [0193], [0288], [0313]-[0315], [0442], [0550], [0552], [0555]. * [Y] 4, 5/4, 10/5/4, 11/10/5/4, 12/5/1-4, 13/5/4, 14/5/4, 15-20; | [Y]JP2015123031 (UNIV CHIBA, et al) [Y] 15-20 * ; English translation; abstract; paragraphs [0017]-[0018], [0062]. *; | [Y]US2014099311 (CHEN YAN [US], et al) [Y] 19 * ; paragraphs [0011], [0080], [0122]. *; | [Y]US2006188502 (GILES-KOMAR JILL [US], et al) [Y] 20 * ; paragraphs [0017]-[0018], [0032], [0059], [0063]. * | [Y] - RHEE et al., "A Phase 2, Open-label, Multicenter Study Of The Long-Term Safety Of Siltuximab (An Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman Disease", Oncotarget., (20150803), vol. 6, no. 30, pages 30408 - 30419, XP055441655 [Y] 4, 5/4, 10/5/4, 11/10/5/4, 12/5/1-4, 13/5/4, 14/5/4 * ; abstract; page 30409, first column, first paragraph; page 30417, second column, first and third paragraphs. * DOI: http://dx.doi.org/10.18632/oncotarget.4655 | [Y] - NAKANISHI et al., "lnterleukin-6/Soluble Interleukin-6 Receptor Signaling Attenuates Proliferation And Invasion, And Induces Morphological Changes Of A Newly Established Pleomorphic Malignant Fibrous Histiocytoma Cell Line", American Journal Of Pathology., (20040801), vol. 165, no. 2, doi:10.1016/S0002-9440(10)63312-3, ISSN 0002-9440, pages 471 - 480, XP055579264 [Y] 16 * ; table 1; page 473, second column first paragraph. * DOI: http://dx.doi.org/10.1016/S0002-9440(10)63312-3 |